News stories about Axsome Therapeutics (NASDAQ:AXSM) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Axsome Therapeutics earned a coverage optimism score of 0.19 on Accern’s scale. Accern also gave media stories about the company an impact score of 46.1496450217795 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the news articles that may have impacted Accern Sentiment’s scoring:
Shares of Axsome Therapeutics (AXSM) traded down $0.02 during midday trading on Thursday, hitting $3.40. 776,253 shares of the stock traded hands, compared to its average volume of 519,133. The company has a quick ratio of 3.86, a current ratio of 3.86 and a debt-to-equity ratio of 0.44. Axsome Therapeutics has a 52-week low of $3.20 and a 52-week high of $6.45. The firm has a market capitalization of $86.53 and a price-to-earnings ratio of -2.50.
Several brokerages recently commented on AXSM. Zacks Investment Research downgraded Axsome Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, December 13th. Cantor Fitzgerald set a $13.00 price target on Axsome Therapeutics and gave the stock a “buy” rating in a report on Friday, December 1st. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $16.90.
WARNING: This report was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another website, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/01/11/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-axsome-therapeutics-axsm-stock-price.html.
About Axsome Therapeutics
Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain.
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.